12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Company News  |  Deals

Ildong, TG Therapeutics deal

TG Therapeutics granted Ildong exclusive rights to develop and commercialize ublituximab in South Korea and Southeast Asia. TG Therapeutics will receive $2 million up front and is eligible...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >